Literature DB >> 10390242

In vitro activities of the everninomicin SCH 27899 and other newer antimicrobial agents against Borrelia burgdorferi.

L L Dever1, C V Torigian, A G Barbour.   

Abstract

The in vitro activity of the everninomicin antibiotic SCH 27899 against 17 isolates of Borrelia spp. was investigated. MICs ranged from 0.06 to 0.5 microg/ml. Time-kill studies with the B31 strain of B. burgdorferi demonstrated >/=3-log10-unit killing after 72 h with concentrations representing four times the MIC. The in vitro activity of four other newer antimicrobial agents, meropenem, cefepime, quinupristin-dalfopristin, and linezolid, was also tested against the B31 strain. Meropenem was the most potent of the latter agents, with an MIC of 0.125 microg/ml.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10390242      PMCID： PMC89363     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  9 in total

Review 1.  The Lyme disease controversy. Social and financial costs of misdiagnosis and mismanagement.

Authors:  L H Sigal
Journal:  Arch Intern Med       Date:  1996-07-22

2.  Comparative in-vitro activity of SCH 27899, a novel everninomicin, and vancomycin.

Authors:  C Urban; N Mariano; K Mosinka-Snipas; C Wadee; T Chahrour; J J Rahal
Journal:  J Antimicrob Chemother       Date:  1996-02       Impact factor: 5.790

Review 3.  Quinupristin/dalfopristin: spectrum of activity, pharmacokinetics, and initial clinical experience.

Authors:  D E Low
Journal:  Microb Drug Resist       Date:  1995       Impact factor: 3.431

4.  Antimicrobial Activity of SCH 27899, Oligosaccharide Member of the Everninomycin Class with a Wide Gram-Positive Spectrum.

Authors:  Ronald N. Jones; Mary S. Barrett
Journal:  Clin Microbiol Infect       Date:  1995-09       Impact factor: 8.067

5.  In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones.

Authors:  R N Jones; D M Johnson; M E Erwin
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

6.  In vitro antimicrobial susceptibility testing of Borrelia burgdorferi: a microdilution MIC method and time-kill studies.

Authors:  L L Dever; J H Jorgensen; A G Barbour
Journal:  J Clin Microbiol       Date:  1992-10       Impact factor: 5.948

7.  In vitro inhibition of Borrelia burgdorferi growth by antibodies.

Authors:  A Sadziene; P A Thompson; A G Barbour
Journal:  J Infect Dis       Date:  1993-01       Impact factor: 5.226

8.  Phylogenetic analysis of the spirochetes.

Authors:  B J Paster; F E Dewhirst; W G Weisburg; L A Tordoff; G J Fraser; R B Hespell; T B Stanton; L Zablen; L Mandelco; C R Woese
Journal:  J Bacteriol       Date:  1991-10       Impact factor: 3.490

9.  In vitro activity of vancomycin against the spirochete Borrelia burgdorferi.

Authors:  L L Dever; J H Jorgensen; A G Barbour
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191
  9 in total
  6 in total

Review 1.  Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections.

Authors:  H M Lamb; D P Figgitt; D Faulds
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

2.  Efficacy of an evernimicin (SCH27899) in vitro and in an animal model of Lyme disease.

Authors:  C S Pavia; G P Wormser; J Nowakowski; A Cacciapuoti
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

Review 3.  Antimicrobial susceptibility of Borrelia burgdorferi sensu lato: what we know, what we don't know, and what we need to know.

Authors:  Klaus-Peter Hunfeld; Volker Brade
Journal:  Wien Klin Wochenschr       Date:  2006-11       Impact factor: 1.704

Review 4.  Antimicrobial growth promoters used in animal feed: effects of less well known antibiotics on gram-positive bacteria.

Authors:  Patrick Butaye; Luc A Devriese; Freddy Haesebrouck
Journal:  Clin Microbiol Rev       Date:  2003-04       Impact factor: 26.132

5.  Structures of the orthosomycin antibiotics avilamycin and evernimicin in complex with the bacterial 70S ribosome.

Authors:  Stefan Arenz; Manuel F Juette; Michael Graf; Fabian Nguyen; Paul Huter; Yury S Polikanov; Scott C Blanchard; Daniel N Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  2016-06-21       Impact factor: 11.205

6.  Evaluation of the preventive capacities of a topically applied azithromycin formulation against Lyme borreliosis in a murine model.

Authors:  Jens Knauer; Inke Krupka; Christiane Fueldner; Joerg Lehmann; Reinhard K Straubinger
Journal:  J Antimicrob Chemother       Date:  2011-09-15       Impact factor: 5.790
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.